MolecuLight Inc | Advanced Wound Care Solutions

MolecuLight i:X^® & DX™

FDA CLEARED

Learn how they work:

Breaking Biases Webcast slide

Jonathan Johnson Webcast slide

Martha Kelso Webcast slide

MolecuLight Announces Presentation of its Clinical and Surgical Benefits in Reconstructive Plastic Surgery by Dr. Michael Desvigne at the 47th Annual JAB Maui Burn & Wound Symposium

MolecuLight was recently featured in:

MolecuLight i:X & DX may help at every stage of wound care

MolecuLight i:X device, front

Assessment

Cleaning

Debridement

Sampling

Documentation

Treatment Selection

Antibiotic Stewardship

Patient Engagement

Assessment

Visualize fluorescent bacteria and measure wound surface area in real-time to understand the status of the wound more fully.^1,3

Watch MolecuLight i:X in action

The MolecuLight i:X Wound Imaging Device allows clinicians to quickly, safely, and easily visualize bacteria² and measure wounds⁷ at the point of care, so they have maximum insights for accurate treatment selection and accelerated healing.

New peer-reviewed publications featuring MolecuLight appeared in:

View All Publications Featuring MolecuLight

Real-Time Detection of Asymptomatic Bioburden in Wounds

Use of the MolecuLight i:X to image for bacterial fluorescence, in conjunction with clinical signs & symptoms, adds an additional bacterial-specific piece of information that can be captured and considered in real-time.

See Full Case Study

Testimonials

"The MolecuLight i:X gives clinicians the ability to visualize and therefore target treatment towards clinically undetectable critical colonization. This user friendly point-of-care device is an exciting addition to our wound care protocol."

David Russell, MD // Leeds Teaching Hospitals, Leeds, UK

"The MolecuLight i:X has transformed my clinical decision making. MolecuLight i:X helps reveal the unexpected and eliminates guess work."

Rosemary Hill, BSN CWOCN CETN(C) // Vancouver Coastal Health, North Vancouver, Canada

"The MolecuLight i:X gives clinicians the ability to visualize and therefore target treatment towards clinically undetectable critical colonization. This user friendly point-of-care device is an exciting addition to our wound care protocol."

David Russell, MD // Leeds Teaching Hospitals, Leeds, UK

"The MolecuLight i:X gives clinicians the ability to visualize and therefore target treatment towards clinically undetectable critical colonization. This user friendly point-of-care device is an exciting addition to our wound care protocol."

David Russell, MD // Leeds Teaching Hospitals, Leeds, UK

Ready to see the difference?

MolecuLight Headquarters

425 University Avenue
Suite 700
Toronto, ON M5G 1T6
Canada

US Address
MolecuLight Corp.
2403 Sidney Street,
Suite 286
Pittsburgh, PA 15203

T. +1 647-362-4684
North American Toll Free:
1-877-818-4360
F.+1 647-362-4730
E: info@moleculight.com

Sitemap

MolecuLight is SOC ll^®
Type l Accredited:

MolecuLight awarded
Premier’s Technology
Breakthrough Designation

MolecuLight i:X
is designated as a:

MolecuLight included
in ISWCAP Consensus
Guidelines:

MolecuLight is a proud
corporate member of:

Global

USA

©2025
The MolecuLight® i:X and MolecuLightDX™ Imaging Devices are approved by Health Canada for sale in Canada and has CE marking for sale in the European Union.
The MolecuLight™ i:X and DX Imaging Devices have received FDA clearance.

References

Wu YC, Smith M, Chu A, Lindvere-Teene L, Starr D, Tapang K, Wong O, Linden R, DaCosta RS. Handheld fluorescence imaging device detects subclinical wound infection in an asymptomatic patient with chronic diabetic foot ulcer: a case report. International Wound Journal, 2016, 13(4), 449-53. doi: 10.1111/iwj.12451.
DaCosta RS, Kulbatski I, Lindvere-Teene L, Starr D, Blackmore K, Silver JI, Opoku J, Wu YC, Medeiros PJ, Xu W, Xu L, Wilson BC, Rosen C, Linden R. Point-of-care autofluorescence imaging for real-time sampling and treatment guidance of bioburden in chronic wounds: first-in-human results. PLOS ONE, 2015, 10(2). doi: 10.1371/journal.pone.0116623.
Ottolino-Perry K, Chamma E, Blackmore KM, Lindvere-Teene L, Starr D, Tapang K, Rosen CF, Pitcher B, Panzarella T, Linden R, DaCosta RS. Improved detection of clinically relevant wound bacteria using autofluorescence image-guided sampling in diabetic foot ulcers. International Wound Journal, 2017, 14(5), 833-841. doi: 10.1111/iwj.12717.
Rennie MY, Lindvere-Teene L, Tapang K, Linden R. Point-of-care fluorescence imaging predicts the presence of pathogenic bacteria in wounds: a clinical study. Journal of Wound Care, 2017, 26(8), 452-460. doi: 10.12968/jowc.2017.26.8.452.
Raizman R. Point-of-care fluorescence imaging device guides care and patient education in obese patients with surgical site infections. Presented at CAWC 2016. Proceedings of the Annual Canadian Association of Wound Care Conference; 2016 Nov 3-6, Niagara Falls, ON, Canada.
Jeffery S. Utility of point-of-care autofluorescence imaging device in successful closure of major limb amputations – a case study. Presented at MHSRS 2016. Proceedings of the Military Health System Research Symposium; 2016 Aug 15-18; Kissimmee, FL, USA.
Dunham D, Teene L. Objective wound measurement software on a point-of-care, hand-held fluorescence imaging device: verification of measurement accuracy and repeatability. Presented at EWMA 2018. Proceedings of the Annual European Wound Management Association Conference; 2018 May 9-11; Krakow, Poland.
Wu YC, Kulbatski I, Medeiros PJ, Maeda A, Bu J, Xu L, Chen Y, DaCosta RS. Autofluorescence imaging device for real-time detection and tracking of pathogenic bacteria in a mouse skin wound model: preclinical feasibility studies. Journal of Biomedical Optics, 2014, 19(8). doi: 10.1117/1.JBO.19.8.085002.
Raizman R, DaCosta RS. Handheld real-time fluorescence imaging of bacteria guides treatment selection and timing of dressing changes in inpatients undergoing negative pressure wound therapy. Presented at IWH 2016. Proceedings of the Innovations in Wound Healing Conference; 2016 Dec 8-11, Key Largo, FL, USA.
Landis S, Rennie MY, Blumenthal E, Jeffery S. Use of fluorescence imaging in visualizing bacteria in chronic ulcers and traumatic soft tissue damage. Presented at AMSUS 2016. Proceedings of the Annual Meeting of the Society of Federal Health Professionals; 2016 Nov 29-Dec 2; National Harbor, MD, USA.
Landis S. Mapping venous ulcers using bacterial autofluorescence (BAF) to identify subgroups at risk of infection post debridement. Presented at CAWC 2016. Proceedings of the Annual Canadian Association of Wound Care Conference; 2016 Nov 3-6, Niagara Falls, ON, Canada.
Hill R, Douglas JJ. Effect of bacterial fluorescence imaging on patient care and wound management in a hospital setting: a pilot study. Presented at SAWC Spring 2017. Proceedings of the Annual Symposium on Advanced Wound Care; 2017 Apr 5-9; San Diego, CA, USA.
Hill R, Douglas JJ. Real-time bacterial fluorescence imaging guides antimicrobial stewardship in patients with diverse wounds. Presented at SAWC Spring 2017. Proceedings of the Annual Symposium on Advanced Wound Care; 2017 Apr 5-9; San Diego, CA, USA.
MolecuLight Inc. PN 1189 MolecuLight i:X User Manual. 2016.
Raizman R. Fluorescence imaging positively predicts bacterial presence and guides wound cleaning and patient education in a series of pilonidal sinus patients. Presented at Wounds UK 2016. Proceedings of the Annual Wounds UK Conference; 2016 Nov 14-16; Harrogate, UK.